NCT00843154View on ClinicalTrials.gov

Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure

PHASE3TerminatedINTERVENTIONAL
Enrollment

571

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Heart Failure
Interventions
DRUG

Candesartan and standard chronic heart disease therapy

Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.

DRUG

Standard chronic heart disease therapy

Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY